Home > [2025-10-23] HKSH Medical Group Announces World’s First Study on Multi-Target, Real-Time Stereotactic Total Ablative Radiotherapy with MR-LINAC for Oligometastatic Prostate Cancer Achieving 100% 3-Year Survival Rate without Severe Side Effects
[2025-10-23] HKSH Medical Group Announces World’s First Study on Multi-Target, Real-Time Stereotactic Total Ablative Radiotherapy with MR-LINAC for Oligometastatic Prostate Cancer Achieving 100% 3-Year Survival Rate without Severe Side Effects